AMRI can do Nemus's cannabinoid chemistry.

The article reports that Nemus has signed up a respected contract research and manufacturing organization Albany Molecular Research Inc. (AMRI) to develop and produce the active ingredient in its lead product. Topics discussed include stock of Zynerba Pharmaceuticals which is developing transdermal synthetic cannabinoids, capitalize on growing interest in cannabinoids and views of Brian Murphy, chief executive officer (CEO) at Nemus, on the same.